Psychedelic Stocks

Expert Explains Why Psychedelic Microdosing Could Transform Productivity

Microdosing is the practice of consuming low doses of psychedelic substances such as psilocybin mushrooms or LSD. This allows an individual to gain the benefits of the drugs without experiencing any psychoactive effects.

Peggy Van de Plassche, a microdosing expert and author, recently discussed the benefits of microdosing and the stigma surrounding psychedelics on the Future of Work podcast.

Van de Plassche’s personal journey with psychedelics, which started as a quest to improve her mental health, greatly influenced her current path. Her experience with psychedelics caused significant positive changes in her mental well-being, leading her to advocate for psychedelics integration into the healthcare and wellness systems.

According to Van de Plassche, microdosing could help improve depressive and anxiety symptoms as well as build resilience against stress, which positively impacts an individual’s quality of life and overall productivity. Microdosing also calms an individual’s nervous system, alleviating their mental burden and enhancing mood stability and overall mood.

The practice may also improve workplace wellness by improving the connection one has to themselves and others. Improved communication skills and increased empathy may also contribute to better relationships in the workplace and more mindful leadership. In addition to this, microdosing may boost an individual’s performance by increasing creativity, attention and focus. This makes individuals more effective problem-solvers and collaborators.

While evidence has shown that psychedelics may be beneficial in the treatment of various mental-health disorders, there still exists stigma rooted in the misconceptions that came up in the 1970s. At the time, psychedelics were linked to negative stories.

This stigma still rears its head today, even though more individuals are exploring the drugs’ benefits. Education is needed to overcome these outdated stigmas. By encouraging open conversations and sharing credible information, public perception of these drugs can shift and pave the way for the acceptance and use of psychedelics.

With more than 970 million individuals in the world living with a mental disorder, prioritizing the well-being and mental health of employees is equally important.

Companies may benefit from microdosing because their workforces will be better connected, more focused and less stressed. Improved mental health also correlates directly with improved productivity, increased job satisfaction and reduced rates of burnout.

This doesn’t mean that getting microdosing accepted in the workplace will be an easy feat. The fragmented legal landscape in the United States where legislation on psychedelics varies by state, country, city and federal jurisdictions doesn’t help either.

At the moment, however, enterprises focusing on developing psychedelic medicines, such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), are looking to the clinical use of these treatments with a prescription from a qualified medical practitioner. Microdosing, which is self-prescribed, is still off the table for these businesses.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

3 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago